John G McHutchison

Summary

Publications

  1. ncbi request reprint The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity
    J G McHutchison
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Hepatol 34:140-7. 2001
  2. ncbi request reprint Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection
    Stephen Pianko
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Interferon Cytokine Res 22:483-9. 2002
  3. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
  4. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007
  5. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
  6. ncbi request reprint Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
  7. ncbi request reprint Hepatitis C advances in antiviral therapy: what is accepted treatment now?
    John G McHutchison
    Division of Gastroenterology and Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road, N203, La Jolla, CA 92037, USA
    J Gastroenterol Hepatol 17:431-41. 2002
  8. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003

Collaborators

Detail Information

Publications8

  1. ncbi request reprint The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity
    J G McHutchison
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Hepatol 34:140-7. 2001
    ..Interferon plus ribavirin is the most effective therapy for chronic hepatitis C. The aim of this study was to evaluate the effect of chronic hepatitis C and therapy on health-related quality of life and work functioning...
  2. ncbi request reprint Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection
    Stephen Pianko
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Interferon Cytokine Res 22:483-9. 2002
    ..IFN monotherapy nonresponder patients tended to have a higher HIC. With IFN plus ribavirin, the sustained virologic response rate was not affected by the HIC...
  3. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  4. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007
    ..Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited...
  5. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
    ..To explore safety, pharmacokinetics, and pharmacodynamics of oral administration of resiquimod, a Toll-like receptor 7 and 8 agonist that induces endogenous interferon-alpha, in subjects with chronic hepatitis C virus infection...
  6. ncbi request reprint Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  7. ncbi request reprint Hepatitis C advances in antiviral therapy: what is accepted treatment now?
    John G McHutchison
    Division of Gastroenterology and Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road, N203, La Jolla, CA 92037, USA
    J Gastroenterol Hepatol 17:431-41. 2002
    ..They will thus provide an incremental benefit in terms of efficacy, particularly for genotype 1-infected patients...
  8. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003
    ..In conclusion, IL-12 as monotherapy at the doses used in this trial for chronic hepatitis C has low efficacy, was poorly tolerated, and is unlikely to provide an alternative to conventional IFN-based therapy...